Radiomedix, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

64Cu-DOTATATE · Oncology; Diagnostic Imaging
64Cu-DOTATATE is a radioactive diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing detection via positron emission tomography (PET).

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Radiomedix, Inc. portfolio CI brief
Radiomedix, Inc. pipeline updates RSS

Frequently asked questions about Radiomedix, Inc.

What is Radiomedix, Inc.'s pipeline?

Radiomedix, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include 64Cu-DOTATATE.

Sector hub: All tracked pharma companies